Although the Federal Trade Commission (“FTC”) continues to scrutinize mergers involving pharmaceutical companies, recent enforcement suggests that, in some cases, transactions presenting discrete competitive issues may still find a path to clearance through targeted divestitures. The FTC’s recent consent order permitting Aurobindo Pharma’s acquisition of Lannett Company to proceed is the latest example. The decision provides useful insight into how the Commission currently appears to be evaluating, and resolving, competitive concerns in the life sciences sector.
The FTC alleged that Aurobindo’s acquisition of Lannett would substantially lessen competition in four markets for generic pharmaceutical products: (1) mycophenolate mofetil oral suspension, (2) niacin extended-release tablets, (3) pilocarpine tablets, and (4) rabeprazole sodium delayed-release tablets. According to the Commission, the transaction would eliminate important head-to-head competition between the parties, increasing the likelihood of both unilateral price increases and coordinated interaction among the remaining manufacturers. Rather than seeking to block the acquisition in its entirety, however, the FTC accepted a proposed consent order requiring Aurobindo to divest the overlapping product lines and related assets to Quagen Pharmaceuticals.[1]
From a substantive perspective, the Commission’s complaint relies on well-established Section 7 principles: the elimination of direct competition, increased concentration, barriers to entry, unilateral effects, and the potential for coordinated effects. Those theories closely track the analytical framework reflected in the 2023 Merger Guidelines, underscoring that, at least in the context of horizontal pharmaceutical mergers, the FTC continues to rely on conventional theories of competitive harm rather than novel approaches to merger analysis.[2]
The complaint also reflects the FTC’s continued emphasis on protecting future price competition in generic pharmaceutical markets. As the Commission explains in its Analysis to Aid Public Comment, therapeutically equivalent generic pharmaceuticals are largely commoditized, and prices are often inversely correlated with the number of competitors in a market. Against that backdrop, the FTC viewed the elimination of a significant competitor as likely to increase the risk of both unilateral price increases and coordinated interaction among the remaining manufacturers.
Perhaps the more noteworthy aspect of the decision lies in the Commission’s approach to remedy. Rather than treating the transaction as irredeemably anticompetitive, the FTC concluded that the identified competitive concerns could be addressed through divestitures to an acceptable purchaser. In doing so, the Commission devoted considerable attention not only to the assets being transferred, but also to Quagen’s experience, resources, and ability to commercialize and compete using those assets.[3] Whether divestitures can restore competition as effectively as an eliminated rivalry is difficult to predict, but the consent decree underscores that identifying a purchaser the FTC views as capable of replacing the lost competition remains a critical component of pharmaceutical merger planning.
The decision also provides a useful point of comparison to recent merger enforcement practice. Although the FTC under the prior administration often expressed greater skepticism toward negotiated merger remedies, the Aurobindo/Lannett consent decree suggests that the Commission is presently willing to employ structural divestitures where it concludes they fully resolve the alleged competitive harm.[4] For parties contemplating acquisitions in the pharmaceutical sector, that approach may provide greater predictability even as substantive merger review remains rigorous.
Although every transaction will turn on its own facts, Aurobindo/Lannett offers a useful reminder that, in pharmaceutical mergers involving discrete product overlaps, the central question may not simply be whether the FTC identifies a competitive concern, but whether the parties can demonstrate that a carefully structured divestiture will adequately address those concerns while permitting the broader transaction to proceed.
[1] In the Matter of Aurobindo Pharma Ltd. and Lannett Company, Inc., Complaint, Docket No. C-4834 (June 2026); Decision and Order (Proposed); FTC Press Release, FTC Takes Action to Protect Americans from Higher Drug Costs in Aurobindo-Lannett Deal (June 18, 2026).
[2] U.S. Department of Justice & Federal Trade Commission, 2023 Merger Guidelines (Dec. 18, 2023), Guidelines 1–4; Aurobindo Pharma Ltd. and Lannett Company, Inc., Complaint ¶¶ __ (alleging elimination of head-to-head competition, increased concentration, barriers to entry, unilateral effects, and coordinated effects).
[3] FTC, Analysis of Proposed Decision and Order to Aid Public Comment, In the Matter of Aurobindo Pharma Ltd. and Lannett Company, Inc. (June 2026) (discussing Quagen Pharmaceuticals’ qualifications and the assets to be divested).
[4] See FTC withdrawal of the 2020 Vertical Merger Guidelines (2021); cf. FTC, Aurobindo Pharma Ltd. and Lannett Company, Inc. (Decision and Order, Proposed) (2026).